Literature DB >> 31904596

Glaucoma screening: where are we and where do we need to go?

Nicholas Y Q Tan1, David S Friedman2,3, Ingeborg Stalmans4, Iqbal Ike K Ahmed5, Chelvin C A Sng1,6.   

Abstract

PURPOSE OF REVIEW: Current recommendations for glaucoma screening are decidedly neutral. No studies have yet documented improved long-term outcomes for individuals who undergo glaucoma screening versus those who do not. Given the long duration that would be required to detect a benefit, future studies that may answer this question definitively are unlikely. Nevertheless, advances in artificial intelligence and telemedicine will lead to more effective screening at lower cost. With these new technologies, additional research is needed to determine the costs and benefits of screening for glaucoma. RECENT
FINDINGS: Using optic disc photographs and/or optical coherence tomography, deep learning systems appear capable of diagnosing glaucoma more accurately than human graders. Eliminating the need for expert graders along with better technologies for remote imaging of the ocular fundus will allow for less expensive screening, which could enable screening of individuals with otherwise limited healthcare access. In India and China, where most glaucoma remains undiagnosed, glaucoma screening was recently found to be cost-effective.
SUMMARY: Recent advances in artificial intelligence and telemedicine have the potential to increase the accuracy, reduce the costs, and extend the reach of screening. Further research into implementing these technologies in glaucoma screening is required.

Entities:  

Mesh:

Year:  2020        PMID: 31904596     DOI: 10.1097/ICU.0000000000000649

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  8 in total

Review 1.  A Comprehensive Review of Methods and Equipment for Aiding Automatic Glaucoma Tracking.

Authors:  José Camara; Alexandre Neto; Ivan Miguel Pires; María Vanessa Villasana; Eftim Zdravevski; António Cunha
Journal:  Diagnostics (Basel)       Date:  2022-04-08

2.  Evaluating machine learning classifiers for glaucoma referral decision support in primary care settings.

Authors:  Omkar G Kaskar; Elaine Wells-Gray; David Fleischman; Landon Grace
Journal:  Sci Rep       Date:  2022-05-20       Impact factor: 4.996

3.  Cluster-randomised trial of community-based screening for eye disease in adults in Nepal: the Village-Integrated Eye Worker Trial II (VIEW II) trial protocol.

Authors:  Kieran S O'Brien; Valerie M Stevens; Raghunandan Byanju; Ram Prasad Kandel; Gopal Bhandari; Sadhan Bhandari; Jason S Melo; Travis C Porco; Thomas M Lietman; Jeremy D Keenan
Journal:  BMJ Open       Date:  2020-10-15       Impact factor: 2.692

4.  Deep learning on fundus images detects glaucoma beyond the optic disc.

Authors:  Ruben Hemelings; Bart Elen; João Barbosa-Breda; Matthew B Blaschko; Patrick De Boever; Ingeborg Stalmans
Journal:  Sci Rep       Date:  2021-10-13       Impact factor: 4.379

5.  Real-Time Risk Score for Glaucoma Mass Screening by Spectral Domain Optical Coherence Tomography: Development and Validation.

Authors:  Kota Fukai; Ryo Terauchi; Takahiko Noro; Shumpei Ogawa; Tomoyuki Watanabe; Toru Nakagawa; Toru Honda; Yuya Watanabe; Yuko Furuya; Takeshi Hayashi; Masayuki Tatemichi; Tadashi Nakano
Journal:  Transl Vis Sci Technol       Date:  2022-08-01       Impact factor: 3.048

6.  Glaucoma Screening: Is AI the Answer?

Authors:  Shibal Bhartiya
Journal:  J Curr Glaucoma Pract       Date:  2022 May-Aug

Review 7.  Telemedicine in ophthalmology in view of the emerging COVID-19 outbreak.

Authors:  Adir C Sommer; Eytan Z Blumenthal
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-08-19       Impact factor: 3.117

8.  Artificial Intelligence and OCT Angiography in Full Thickness Macular Hole. New Developments for Personalized Medicine.

Authors:  Stanislao Rizzo; Alfonso Savastano; Jacopo Lenkowicz; Maria Cristina Savastano; Luca Boldrini; Daniela Bacherini; Benedetto Falsini; Vincenzo Valentini
Journal:  Diagnostics (Basel)       Date:  2021-12-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.